Vaccine shield tested for vulnerable transplant patients
NCT ID NCT06593210
Summary
This study is testing a vaccine to prevent serious Respiratory Syncytial Virus (RSV) infections in adults who have received a lung or stem cell transplant. These patients have weakened immune systems and are at high risk from viruses like RSV. Researchers will give 100 participants a single dose of the vaccine and check their blood over a year to see if it safely triggers a strong immune response and prevents RSV illness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network
RECRUITINGToronto, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.